Broncano-Lavado Antonio, Santamaría-Corral Guillermo, Esteban Jaime, García-Quintanilla Meritxell
Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Av. Reyes Católicos, 2, 28040 Madrid, Spain.
Antibiotics (Basel). 2021 Jun 4;10(6):672. doi: 10.3390/antibiotics10060672.
The increase of multiresistance in bacteria and the shortage of new antibiotics in the market is becoming a major public health concern. The World Health Organization (WHO) has declared critical priority to develop new antimicrobials against three types of bacteria: carbapenem-resistant , carbapenem-resistant and carbapenem-resistant and ESBL-producing . Phage therapy is a promising alternative therapy with renewed research in Western countries. This field includes studies in vitro, in vivo, clinical trials and clinical cases of patients receiving phages as the last resource after failure of standard treatments due to multidrug resistance. Importantly, this alternative treatment has been shown to be more effective when administered in combination with antibiotics, including infections with biofilm formation. This review summarizes the most recent studies of this strategy in animal models, case reports and clinical trials to deal with infections caused by resistant , , and strains, as well as discusses the main limitations of phage therapy.
细菌多重耐药性的增加以及市场上新抗生素的短缺正成为一个主要的公共卫生问题。世界卫生组织（WHO）已宣布将开发针对三种类型细菌的新型抗菌药物列为关键优先事项：耐碳青霉烯类、耐碳青霉烯类以及耐碳青霉烯类且产超广谱β-内酰胺酶（ESBL）的细菌。噬菌体疗法是一种有前景的替代疗法，在西方国家正重新受到研究。该领域包括体外研究、体内研究、临床试验以及因多重耐药导致标准治疗失败后将噬菌体作为最后手段的患者临床病例。重要的是，这种替代疗法已被证明与抗生素联合使用时更有效，包括对形成生物膜的感染。本综述总结了该策略在动物模型、病例报告和临床试验中针对由耐药的、、和菌株引起的感染的最新研究，并讨论了噬菌体疗法的主要局限性。
